A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAVO101 in Adult Healthy Subjects
Latest Information Update: 09 Apr 2024
At a glance
- Drugs Tavo 101 (Primary)
- Indications Hypersensitivity
- Focus Adverse reactions; First in man
- Acronyms TAVO101-0001
- Sponsors Tavotek Biotherapeutics
- 03 Apr 2024 Planned End Date changed from 31 Jan 2024 to 30 May 2024.
- 10 Dec 2023 Planned End Date changed from 1 Mar 2024 to 31 Jan 2024.
- 09 May 2023 Status changed from recruiting to active, no longer recruiting.